Copper Cu 64 Dotatate Injection - Indications, Side Effects, and Pharmacological Aspects

Overview:

To identify neuroendocrine tumors (NETs) or cancers of the neuroendocrine cells with somatostatin receptors (they are special receivers that are responsible for detecting the hormone somatostatin, which functions as a messenger in the nervous system and brain), positron emission tomography (PET) scans are performed in conjunction with Copper Cu 64 dotatate injection. It is classified as a radiopharmaceutical, meaning it has a radiation content. However, the low radiation content is used to investigate the body's organs' functions or diagnose illnesses. Only medical professionals with specialized training in nuclear medicine should administer this medication. If given by someone else, it has to be under their direct supervision. The drug was approved by the United States Food and Drug Administration (USFDA) in 2020.

Drug Group:

Copper Cu 64 dotatate injection belongs to the drug group called radiopharmaceuticals, which has low radiation content.

Available Doses and Dosage Forms:

For PET imaging, adults should receive an intravenous injection of radioactivity at a dose of 148 MBq (megabecquerel) or 4 mCi (millicuries). This injection takes around one minute to complete.

For Patients:

What Is Positron Emission Tomography?

Positron emission tomography (PET) is an imaging technique. Radiotracers, or trace amounts of radioactive material, are used in nuclear medicine procedures such as PET imaging and PET scans. Physicians use these radiotracers to assess, diagnose, and treat neurological, gastrointestinal, endocrine, and cancerous conditions.

Nuclear medicine examinations are very good at identifying molecular activity, meaning they may identify diseases in their early stages and evaluate how well a treatment is working. Crucially, these operations are noninvasive and, except for intravenous injections, usually involve no discomfort.

How Is a PET Scan Performed?

In the course of a PET scan, a tiny quantity of radioactive tracer is injected into the patient's vein, usually at the elbow. The radiologist can see more organs and tissues as the tracer travels and accumulates in the circulation. The patient needs to wait for about an hour after the tracer is given to allow it to spread throughout the body. After that, the patient lies on a table, gliding into a big scanner resembling a tunnel. This scanner picks up the signals the tracer emits, which a computer interprets into three-dimensional images. The monitor shows these pictures so the medical professional can examine them.

Patient Preparation:

Consider the patient's medication schedule before imaging patients on somatostatin analogs (medications that prevent the overproduction of hormones in the body). While only a two-day interval is suggested for people on short-acting somatostatin analogs, it is recommended that those taking long-acting somatostatin analogs wait 28 days before imaging. For added protection against radiation exposure, patients receiving Copper Cu 64 dotatate should also be well hydrated before injection. They should also keep drinking water and urinate often following administration. Before using Copper Cu 64 dotatate, women of reproductive age should have a pregnancy assessment. These actions are essential for the best imaging results and safety.

Obtaining Images:

It is optimal to scan the full body using Copper Cu 64 dotatate for PET imaging, starting at the top of the head and ending in the middle of the thighs. 45 to 90 minutes after injecting Copper Cu 64 dotatate intravenously, begin imaging. To obtain the best images possible, modify the scan's timing and duration according to the type of equipment, the unique qualities of the patient, and the tumor. This guarantees the highest quality images for planning a diagnosis and course of therapy.

Image Interpretation:

Copper Cu 64 dotatate binds to the body's somatostatin receptors upon injection. PET pictures obtained later reveal the number of receptors and the strength of their signals in various organs. This aids in locating somatostatin receptor-containing tissues or malignancies. It is occasionally possible for absorption to be seen in both normal body variants and other tumor kinds that carry these receptors. However, tumors devoid of somatostatin receptors will not appear in these images.

What Are the Things to Inform the Doctor Before Taking Copper Cu 64 Dotatate Injection?

• Patients should list out all the over-the-counter medications, medical history, and current drug regimes to their doctors before taking Copper Cu 64 dotatate injections.

• Patients must let the doctor know about their pregnancy and breastfeeding status. Though the data based on the research is insufficient to prove the harmful effects on the fetus and baby during lactation, it is advisable to refrain from the use of Copper Cu 64 dotatate injection if pregnant or while lactating.

• People must inform their healthcare professionals if they are taking any specific medications before undergoing a diagnostic test, as these medications may interfere with the test. When combined with a Copper Cu 64 dotatate injection test, medications including Lanreotide, Octreotide, and Pasireotide may cause problems. Although taking these drugs just before the test is generally not advised, there may be circumstances in which it is required. To lessen any possible negative effects in such circumstances, the doctor may decide to change the medication's dosage or the test's frequency.

• If a patient has had any strange or allergic reactions to other prescriptions or Copper Cu 64 dotatate injection, they should inform their doctor. They should also inform their healthcare provider about any additional allergies, such as those to foods, colors, preservatives, or animals.

Why Is Crucial Monitoring Necessary While Using Copper Cu 64 Dotatate Injection?

When Copper Cu 64 dotatate injectionis administered, their physicians must closely observe patients to ensure its effectiveness and assess if further use of the prescription is necessary. Serious allergic responses, including anaphylaxis (fatal allergic reaction) and angioedema (swelling which is caused by an allergic reaction that is painless), which call for emergency medical intervention, are possible with this medicine. Chest tightness, coughing, trouble swallowing, dizziness, fast heartbeat, hives, itching, skin rash, swelling of different body parts, breathing difficulties, or extreme exhaustion are some of the symptoms that may be experienced. Furthermore, the risk of cancer is increased if radiation is received while using this medicine. It is recommended that patients instantly inform their healthcare professional if they encounter any troubling symptoms or have inquiries about the possible hazards linked to the medication.

Dietary Instructions: Hydration is very important; hence, the patient is asked to drink lots of water before and after the Copper Cu 64 dotatate administration.

Missed Dose: Copper Cu 64 dotatate is always provided under medical supervision (professionals trained in nuclear medicine).

Overdose:

It is important to work toward lowering the patient's absorbed dose in the event of a radiation overdose. Removing radioactive particles from the body upon Copper Cu 64 dotatate injectioncan be facilitated by increasing fluid intake and encouraging regular urine. A diuretic may also be used to help with this procedure. Estimating the patient's radiation exposure is advisable if feasible.

Safety and Handling: It is imperative to adhere to certain safety precautions to handle Copper Cu 64 dotatate and reduce radiation exposure properly. This involves wearing radiation-resistant gloves and using efficient radiation shielding during preparation and handling. Furthermore, the only doctors who should use Copper Cu 64 dotatate have been certified by the government to handle radionuclides and have undergone specialized training. These medical professionals have the expertise to handle radiopharmaceuticals properly, protecting others and oneself from possible radiation risks.

For Doctors

Indication - Neuroendocrine tumors (NETs) in adult patients with somatostatin receptors are detected using Cu 64 Dotatate Injectionin conjunction with positron emission tomography (PET) images.

Contraindication - None.

How Is Copper Cu 64 Dotatate Administered?

Certain requirements must be followed to guarantee accuracy and safety when using Copper Cu 64 dotatate. Copper Cu 64 dotatate must be administered within two hours of calibration time. Aseptic methods and radiation shielding must be used during administration and withdrawal. Check Copper Cu 64 dotatate visually for discoloration or particles before administering the medication. If found, the medication should not be used. Considering the volume, measured activity, calibration time, and date as a guide determine the volume needed for administration. Before administering the dose to the patient, measure it with a dose calibrator. Give an intravenous flush of 0.9 percent sodium chloride injection, USP (United States Pharmacopeia), after the injection. Any medication not being used should be disposed of safely and in compliance with applicable laws.

What Are the Pharmacological Aspects of Cu 64 Dotatate Injection?

1. Description - Copper Cu 64 dotatate is an intravenous solution that is clear, colorless to yellow, and sterile. Each 10 mL (milliliter) single-dose vial contains 148 MBq (4 mCi) of copper Cu 64 dotatate at the calibration date and time, with a solution volume of 4 mL. In addition, 40 mg (milligram) of ascorbic acid and 0.05 mL of dehydrated alcohol (ethanol) in sterile water for injection (USP) are included in each milliliter of the solution. Sodium hydroxide and hydrochloric acid are used to bring the solution's pH (potential of hydrogen) down to a range of 5.5 to 7.5.

2. Mechanism of Action - High affinity for somatostatin receptors, namely subtype 2 receptors (SSTR2), is shown by Copper Cu 64 dotatate. It binds selectively to cells that produce somatostatin receptors, including cancerous neuroendocrine cells, which frequently overexpress SSTR2 receptors. Since Copper Cu 64 emits positrons (β+), it can be used in positron emission tomography (PET) imaging. This facilitates the identification and visualization of tissues that express somatostatin receptors, which helps diagnose and follow up diseases linked to these receptors, like neuroendocrine tumors.

3. Pharmacodynamics: Clinical trials did not examine the relationship between plasma concentrations of Copper Cu 64 dotatate and imaging efficacy.

4. Pharmacokinetics:

• Distribution: The liver, kidneys, pituitary glands, adrenal glands, and spleen usually have the highest levels of radioactivity within one to three hours following a single dosage of Copper Cu 64 dotatate injection.

• Elimination:

  • Metabolism - Currently, it is unknown how Copper Cu 64 dotatate is metabolized in the body.

  • Excretion - Between 16 percent and 40 percent of the administered amount was excreted in the urine over a six-hour collection period following a single intravenous injection of Copper Cu 64 dotatate.

• Specific Population: Research has not been conducted to determine how renal or hepatic impairment impacts the pharmacokinetics of Copper Cu 64 dotatate.

Nonclinical Toxicology:

No studies have been done on the mutagenic and carcinogenic properties of Copper Cu 64 dotatate injections. However, it is widely known that the radiation that Copper Cu 64 dotatate emits is a mutagen and a carcinogen. As a result, care should be taken when weighing the possible hazards connected to its use.

Furthermore, few studies have been done on animals regarding how Copper Cu 64 dotatate affects embryology or fertility. Further research is needed to determine the impact of Copper Cu 64 dotatate on mutagenicity, carcinogenicity, and fertility.

Drug Interaction:

It is vital to understand that somatostatin analogs and Copper Cu 64 dotatate patients compete with one another for binding to somatostatin receptors (SSTR2). It is recommended that individuals on long-acting somatostatin analogs wait 28 days before getting imaging. However, it is only advised that people using short-acting somatostatin analogs rest for two days before imaging. This lets the competitive binding stabilize and guarantees better imaging results.

Clinical Studies:

Studies suggest that a novel imaging agent, Copper Cu 64 dotatate, may better diagnose neuroendocrine tumors (NETs) more accurately than existing agents. A study employing various doses on 12 patients was done to determine the optimal dose for clear scans. They discovered that the ideal dosage was 148 MBq (4.0 mCi).

This dosage was used for scans on 42 NET-positive patients and 21 healthy subjects. Three physicians examined the images without being aware of the patients' specifics. Accuracy was evaluated by comparing their results with the patient's medical histories. The results for NET detection demonstrated high sensitivity (90.9 percent) and specificity (96.6 percent), and these numbers improved with additional adjustments.

Warnings and Precautions:

• Radiation Risk: Radiation exposure can be increased over time using diagnostic radiopharmaceuticals such as Copper Cu 64 dotatate injection. An increased risk of developing cancer is associated with prolonged radiation exposure. Handling and preparing these materials carefully is essential to protect patients and healthcare personnel from unintentional radiation exposure. Urinating regularly after getting the radiopharmaceutical and drinking lots of fluids before and after should be recommended in the patients. By taking these steps, the danger is decreased by speeding up the removal of the radioactive material from the body.

• The possibility of Misinterpreting an Image: Somatostatin receptor density in neuroendocrine tumors (NETs) is determined by the Copper Cu 64 dotatate uptake. All tumors, including non-cancerous ones like inflammation or thyroid problems, also have these receptors. It does not rule out the potential of having NET even if a scan using Copper Cu 64 dotatate injectionreveals no uptake in those without a relevant medical history.

Specific Considerations:

• Pregnancy - The possibility of harm to a growing baby from all radiopharmaceuticals, including injections of Copper Cu 64 dotatate, varies based on the stage of pregnancy and radiation exposure. It is important to advise expectant mothers of the possible dangers of radiation exposure to their developing fetus from Copper Cu 64 dotatate use. Data on the use of Copper Cu 64 dotatate injections in pregnancy to evaluate the likelihood of miscarriage, birth abnormalities, or other unfavorable consequences for the mother or fetus, however, is not currently available. Furthermore, the injection of Copper Cu 64 dotatate has not been the subject of any animal research. A baseline chance of birth abnormalities, miscarriage, or other unfavorable outcomes exists for every pregnancy, which is crucial to remember.

• Nursing Mother - Information about the presence of Copper Cu 64 dotatate in human milk, its impact on nursing infants, and its effect on milk supply is scarce. There are no studies on animal lactation. To reduce the possibility of radiation exposure affecting breastfed infants, it is recommended that nursing mothers stop breastfeeding for 12 hours after Copper Cu 64 dotatate injections are administered.

• Pediatric Patients - The impact of injecting Copper Cu 64 dotatate on age in children has not been adequately studied. As a result, this injection's effectiveness and safety have not been shown for use in children.

• Geriatric Patients - There were not enough participants in the clinical trials for Copper Cu 64 dotatate injection who were 65 or older to determine whether they reacted differently from younger persons. On the other hand, there does not appear to be a significant difference between older and younger patients' responses, according to various observations and experiences. Still, physicians should exercise caution and typically begin with a low dose when administering Copper Cu 64 dotatate injection to elderly patients. This is because elderly individuals may be more susceptible to problems with their heart, liver, or kidneys, or they may be on other medications that could interfere with their ability to use the Copper Cu 64 dotatate injections.